Trial highlights from EACTS Annual Meeting 2023

Trial highlights from EACTS Annual Meeting 20...

Suivant

Rebuilding a destroyed heart: the Commando procedure

A pioneer of modern cardiac surgery, Tirone David, joins A Cut Above for a deep dive into one of the specialty's most feared and technically demanding operations: the Commando procedure. Also featuring Eduard Quintana, listen for discussions from radical reconstruction for infect ...  Afficher plus

Valve Therapy in 2026: Is Surgery Losing Ground? A Debate with ESC/EACTS Guideline Co-Authors

In this episode, our hosts are joined by Michael Borger and Nikolaos Bonaros to break down the new valvular heart disease guidelines—what's changed, why it matters, and how the decisions were really made. They cut through the headlines to explain the thinking behind key recommend ...  Afficher plus

Épisodes Recommandés

Top Takeaways from 2024: Interventional Cardiology with Deepak L. Bhatt, MD, MPH, MBA, FACC
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

<div class="OutlineElement Ltr SCXW99262018 BCX0">

<span class= "TextRun SCXW99262018 BCX0" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class= "NormalTextRun SCXW99262018 BCX0">In this interview,</span> <span class="NormalTextRu ...

  Afficher plus

Jul 12 2024 This Week in Cardiology
This Week in Cardiology

Venous closure devices, GLP1-s linked to blindness and cancer, resisting the urge to do an ECG, and transcatheter edge-to-edge repair (TEER) for secondary mitral regurgitation are the topics discussed this week.

This podcast is intended for healthcare professionals ...

  Afficher plus

LifeBTK Trial: Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease
Audible Bleeding

In this episode of Audible Bleeding, Jamila, Anh, and Naveed discuss the LifeBTK Trial with Principal Investigator Dr. Brian DeRubertis, where we discuss the new Abbott Esprit everolimus-eluting resorbable scaffold for the below-knee popliteal space. Guest: Dr. DeRubertis, is the ...  Afficher plus

Evolut Low-Risk Trial: 5-year Data Outcomes
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Transcatheter aortic valve replacement (TAVR) has emerged as the preferred treatment for aortic stenosis. However, there is a lack of long-term outcome data for low-risk patients. The 5-year results from the Evolut Low-Risk randomized trial address this gap, offering compelling e ...  Afficher plus